Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 816-821

  Davies, S L ^a,b   Bergh, J ^a   Harris, A L ^a   Hickson, I D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug resistance; ICRF 159; Multidrug resistance; Multidrug resistance related protein; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GLYCOPROTEIN P; RAZOXANE;

ARTICLE; CELL LINE; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0031040036     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.146     Document Type: Article

References (26)

1. Ausubcl FM (1994) Current Protocols in Molecular Biology. John Wiley and Sons: New York
2. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan K (1986) Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer eel Is. J Biol Ciiem 261: 15544-15549
3. Beck WT, Danks MK, \Volverton JS, Kim R and Chen M (1993) Drug resistance associated with altered DNA topoisomerase II. Advan Enzyme Regul 33: 113-127
4. Bradley G and Ling V (1994) P-glycoprotein, multidrug resistance and tumour progression. Cancer Metastasis Rev 13: 223-233
5. Chen M and Beck W (1995) Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer ResSS: 1509-1516
6. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium Ihiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
7. Cole SPC, Bhardwaj G, Gerlach JH. Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258:1650-1654
8. Danks MK, Warmomh MR, Friche E, Granzen B, Bugg BY, Harker G, Zwelling LA, Futscher BW, Suttle DP and Beck WT (1993) Single-strand conformational polymorphism analysis of the Mr 170,000 isozyme of DNA topoisomerase II in human tumour cells. Cancer Res S3: 1373-1379
9. Davies SL, Jenkins JR and Hickson ID (1993) Human cells express two differentially spliced forms of topoisomerase IIβ messenger RNA. Nucl Acids Res 21: 3719-3723
10. Davies SM, Robson CN, Davies SL and Hickson ID (1988) Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Client 263: 17724-17729
11. Fairchild CR, Goldsmith ME and Cowan KH ( 1990) Molecular Biology of Antineoplastic Drug Resistance Cossman J (ed.), pp. 113-141. Elsevier: New York
12. Freemantle SJ, Jackman AL and Kelland LR (1995) Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Confer 71: 925-930
13. Froelich-Ammon S and Osheroff N (I995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Cheat 270: 21429-21432
14. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID (1991) Relationship between topoisomerase II level and chemosensitivity in human tumour cell lines. Cancer Res 51: 6592-6595
15. Glisson B, Gupta R, Smallwood-Kentro S and Ross W (1986) Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934-1938
16. Hoskins L, Whelan R, Shellard S, Davies S, Hickson I, Danks M and Hill B (1994) Multiple mechanisms of resistance in a series of human testicular teratoma cell lines selected for increasing resistance to etoposide. Int J Cancer 57: 259-267
17. Houlbrook S, Addison C, Davies S, Carmichael J, Stratford I, Harris A and Hickson I (1995) Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72: 1454-1461
18. Jaffrezou J, Chen G, Duran G, Kühl J-S and Sikic B (1994) Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Katl Cancer Insr 86: 1152-1158
19. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D and Hickson ID (1992) Isolation of cDNA clones encoding the isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucl Acids Res 20: 5587-5592
20. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
21. Liu LF, Row e TC, Yang L, Tewey KM and Chen GL ( 1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370
22. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand II, O'Brien EE, Poplack DO, Cossman J, Myers CE and Cowan KH (1989) Expression of anionic glutamione S-lransferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49: 1422-1428
23. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32: 103-108
24. Roca J, Ishida R, Berger JM, Andoh T and Wang JC ( 1994) Antitumour bisdio.xopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Nail Acad Sei USA 91: 1781-1785
25. Tanabe K, Ikegami Y, Ishida R and Andoh T (1991) Inhibition of topoisomerase II by antitumour agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908
26. Tsugoshi S (1994) A novel antitumor agent, sobuzoxane (MST-I6). Jpn J Cancer Chemother 21: 1089-1097